Adenosine vs Diltiazem for Treatment of SVT in the ED

Last updated: September 4, 2025
Sponsor: Anne E. Zepeski
Overall Status: Active - Recruiting

Phase

4

Condition

Cardiac Disease

Heart Disease

Heart Defect

Treatment

diltiazem

adenosine

Clinical Study ID

NCT06993038
202412202
  • Ages 18-100
  • All Genders

Study Summary

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult patients (18 years and older)

  2. Diagnosis of acute, stable SVT in the emergency department

Exclusion

Exclusion Criteria:

  1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includesadenosine, non-dihydropyridine calcium channel blockers, beta-antagonists inpre-hospital and/or hospital setting).

  2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome

  3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF</= 40%)

  4. Severe bronchoconstrictive lung disease

  5. Prior hypersensitivity to study medication

  6. Previously enrolled in pilot study

  7. Pregnant

  8. Incarcerated

Study Design

Total Participants: 20
Treatment Group(s): 2
Primary Treatment: diltiazem
Phase: 4
Study Start date:
August 01, 2025
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • University of Iowa Health Care

    Iowa City, Iowa 52242
    United States

    Site Not Available

  • University of Iowa Health Care

    Iowa City 4862034, Iowa 4862182 52242
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.